Trikafta / Kaftrio
Active
Vertex Pharmaceuticals
Overview
Vertex's flagship cystic fibrosis triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor), effective for roughly 90% of CF patients and the company's dominant revenue engine — now complemented by the once-daily next-generation Alyftrek.
The CF standard of care worldwide. Vertex is converting patients onto the once-daily Alyftrek (approved December 2024) and expanding ex-US launches and younger-age labels to sustain franchise growth.